Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.33 |
| ▸ | USP5 | P45974 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10043148 | 1.00 | ESR2 (0.41) | ESR2SLC6A2SLC6A3SLC6A4OPRL1 | |
| SCHEMBL739154 | 0.95 | ESR2 (0.44) | ESR2OPRL1HTR2C | |
| SCHEMBL12917796 | 0.95 | ESR2 (0.44) | ESR2OPRL1HTR2C | |
| SCHEMBL18440774 | 0.95 | ESR2 (0.44) | ESR2OPRL1HTR2C | |
| SCHEMBL20312881 | 0.95 | ESR2 (0.44) | ESR2OPRL1HTR2C | |
| SCHEMBL9979956 | 0.92 | ESR2 (0.47) | ESR2SLC6A2SLC6A3SLC6A4USP5 | |
| SCHEMBL18503359 | 0.92 | ESR2 (0.47) | ESR2SLC6A2SLC6A3SLC6A4USP5 | |
| SCHEMBL15630469 | 0.91 | ESR2 (0.48) | ESR2OPRL1HTR2C | |
| SCHEMBL18499069 | 0.91 | ESR2 (0.48) | ESR2OPRL1HTR2C | |
| SCHEMBL18558911 | 0.90 | ESR2 (0.40) | ESR2OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470199-B2 | Five-ring liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20120074355-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-03-29 | — | — | US | disclosed |
| WO-2010146992-A1 | PENTACYCLIC LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | チッソ株式会社 (JP) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120074355-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | HTR3D, KIF23, CCND3 | ESR2 2435/4885SLC6A2 4212/4885SLC6A3 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.